Letrozole (Femara) 2.5 mg

Letrozole (Femara) 2.5 mg is Hilma Biocare's high-potency non-steroidal aromatase inhibitor, supplied as 30 tablets. It produces the most complete oestrogen suppression of the commonly used aromatase inhibitors.

What Letrozole Is

Letrozole is a third-generation non-steroidal aromatase inhibitor that binds the aromatase enzyme with very high affinity. Aromatase converts androgens such as androstenedione and testosterone into oestrone and oestradiol, so inhibiting it sharply reduces circulating oestrogen. Letrozole is more potent than anastrozole at standard doses and is orally active with good absorption. The 2.5 mg tablet is the standard clinical strength.

The History of Femara

Letrozole was developed by Ciba-Geigy and approved in 1997 as Femara for advanced breast cancer in postmenopausal women. It later became a standard adjuvant therapy, with the BIG 1-98 trial comparing it with tamoxifen and demonstrating improved outcomes. Letrozole has also been studied for ovulation induction, where it has challenged clomiphene as a first-line option. Its potency and consistency made it a benchmark aromatase inhibitor.

How It Works

Letrozole competes with the natural androgen substrate at the aromatase active site, binding reversibly but with very high affinity. The result is profound suppression of oestrogen synthesis in peripheral tissues, particularly fat and muscle. Lower oestrogen removes negative feedback on the pituitary, which can increase gonadotropins. Letrozole is metabolised in the liver and excreted mainly in urine, with a terminal half-life of around two days.

What the Research Shows

• The BIG 1-98 trial compared letrozole with tamoxifen in early breast cancer.
• Letrozole is established as adjuvant therapy in postmenopausal hormone-receptor-positive disease.
• Ovulation-induction trials have compared letrozole with clomiphene.
• Studies consistently show near-complete suppression of circulating oestradiol.

Research Context

Letrozole's potency has made it a useful tool for studying near-complete oestrogen suppression. In ovulation research, it has been compared directly with clomiphene and has shown comparable or better pregnancy rates in some trials, with fewer anti-oestrogenic effects on the endometrium. In oncology, the BIG 1-98 trial compared letrozole with tamoxifen and with sequential regimens, and the results established letrozole as a standard adjuvant option. Bone density and lipid changes are the most studied long-term consequences of profound oestrogen suppression.

Strength, Pack and Authentication

The pack contains 30 tablets of 2.5 mg each, sealed in moisture-resistant blister strips inside a printed carton. The carton states the compound, strength and tablet count, and a scratch-off security code inside the box can be checked against Hilma Biocare's records. Each tablet delivers a consistent 2.5 mg dose.

Buying Femara Online

Femara is one of the most searched aromatase inhibitors. If you are researching letrozole, comparing Femara 2.5 mg products or looking to buy letrozole online from a trusted Hilma Biocare supplier, this page gives you the full specification, pack size, price and live stock status. Browse more Hilma Biocare hormone-support products at NotNatty.